Jeffrey J. Pu, MD, PhD

Clinical and Translational Oncology Program


Dr. Pu received Ph.D. in Developmental Molecular Cell Biology from New York Medical College and MD from Shanghai Jiao Tong University School of Medicine. He completed his Medicine Residency at Mount Sinai School of Medicine. He then completed a NIH-supported experimental hematology fellowship at pioneer Dr. Colvin M. Redman’s laboratory and a clinical transfusion medicine/blood banking fellowship at the LFK Research Institute of New York Blood Center. He eventually completed Hematology/Oncology fellowship supported by NIHT32 training grant at Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University. Dr. Pu is certified as an expert of BMF diseases and a preferred hematologist consultant by the Aplastic Anemia & MDS International Foundation.

Cancer Focus

Dr. Pu’s research interests include hematopoietic mechanism of hematological malignant disease progression, stem cell biology, biomarker translational research, cellular therapy, early phase clinical trials, and HCTT outcome-research. He is credited for first in the world identified and cloned hPD-1 gene and its immune modulating function; identified Kell blood gene-group expression pattern in early hematopoiesis and the cause of Kell alloimmune-induced severe fetal anemia; determined that PNH clone size of 25% as the golden diagnostic standard to predict the risk of significant hemolysis in aplastic anemia (AA); identified the origins of hypocellular myelodysplastic syndromes (MDS) and AA; and identified PIGN gene as a CIN suppressor in MDS progression/leukemic transformation.